Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced that their Alzheimer’s disease therapy, Leqembi (lecanemab), has received approval in the United Arab Emirates (UAE) for the treatment of patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and/or mild AD dementia.
Leqembi is a humanized monoclonal antibody targeting soluble and insoluble aggregates of amyloid-beta (Aβ), a key component of the amyloid plaques associated with AD. The therapy is designed to reduce both Aβ protofibrils and plaques in the brain. In addition to its UAE approval, Leqembi is also registered in the United States, Japan, China, South Korea, Hong Kong, and Israel.- Flcube.com
